If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...
BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...
Everyday Health on MSN
Obstructive vs. Nonobstructive Hypertrophic Cardiomyopathy (HCM): What Your Diagnosis Means for Treatment and Lifestyle
Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...
Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, announced the dosing of the first patient in the phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, ...
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback